Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial

Pemafibrate was superior to fenofibrate in terms of serum TG-lowering effect and hepatic and renal safety.